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Fibrin glue (FG) is used in a variety of clinical applications and in the laboratory for localized and sustained
release of factors potentially important for tissue engineering. However, the effect of different fibrinogen con-
centrations on FG scaffold delivery of bioactive adeno-associated viruses (AAVs) has not been established. This
study was performed to test the hypothesis that FG concentration alters AAV release profiles, which affect AAV
bioavailability. Gene transfer efficiency of AAV-GFP released from FG was measured using HEK-293 cells.
Bioactivity of AAV transforming growth factor-beta1 (TGF-b1) released from FG was assessed using the mink
lung cell assay, and by measuring induction of cartilage-specific gene expression in human mesenchymal stem
cells (hMSCs). Nondiluted FG had longer clotting times, smaller pore sizes, thicker fibers, and slower dissolution
rate, resulting in reduced release of AAV. AAV release and gene transfer efficiency was higher with 25% and
50% FG than with the 75% and 100% FG. AAV-TGF-b1 released from dilute-FG transduced hMSCs, resulting in
higher concentrations of bioactive TGF-b1 and greater upregulation of cartilage-specific gene expression com-
pared with hMSC from undiluted FG. This study, showing improved release, transduction efficiency, and
chondrogenic effect on hMSC of bioactive AAV-TGF-b1 released from diluted FG, provides information im-
portant to optimization of this clinically available scaffold for therapeutic gene delivery, both in cartilage
regeneration and for other tissue engineering applications.
Introduction
The limited repair potential of articular cartilage con-tributes to the development of debilitating osteoar-
thritis, a significant public health challenge.1,2 Clinical
strategies for management of cartilage pathology have
evolved from primarily palliative methods to treat early
disease until joint replacement for end stage disease, toward
more biologic, joint-conserving measures. These include
cartilage reconstruction as in osteochondral graft trans-
plantation,3 and cartilage repair as in bone marrow (BM)
stimulation,4,5 autologous chondrocyte implantation,6 or
stem cell implantation.7 However, results of cartilage repair
procedures have been equivocal, and no single approach
has been shown to be superior.8,9 Therefore, an important
strategy for cartilage repair and tissue engineering is on
investigating utilization of bioactive factors and biode-
gradable scaffolds to promote local, recruited, or trans-
planted cell proliferation and differentiation within
cartilage wounds. Despite the promising results of in vitro
growth factor application, in vivo application has not been
as successful due to the short half-life of these growth fac-
tors and the need for high repetitive dosing as well as a
costly purification process.
Gene therapy can overcome these obstacles by delivering
genes that encode chondrogenic growth factors or inhibitors
of cartilage catabolites in various vector constructs. This also
provides for a local delivery system that drives the expres-
sion of therapeutic molecules over an extended period and
overcome the need for repeated administrations or inter-
ventions. Gene carriers include plasmids, nonviral vectors,
and viral vectors. Although plasmid and nonviral vectors are
less toxic, less immunogenic, and easier to prepare, their
gene delivery efficiencies are significantly lower compared
with viral vectors.10 Hence, viral vectors are currently con-
sidered the most effective agents for in vivo gene transfer.11
Viral vectors that have been used in the preclinical setting
include adenovirus, adeno-associated virus (AAV),12 and
lentivirus.13 AAV is derived from an endemic, nonpathogenic
parvovirus. It has the following advantages over other viru-
ses: sustained transgene expression over longer period,14 re-
duced potential for host immune response, and the capacity
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to transduce both dividing and nondividing cells.15 After
transduction, the viral genome translocates into the target cell
nucleus, and the DNA polymerase generates the transducing
episome. Numerous serotypes of AAV have been identified,
each having different preferential targets. Among the differ-
ent serotypes, AAV serotype 2 (AAV2) is considered to have
the best defined safety profile as it has already been used in
clinical trials.16
There are three general approaches for cartilage viral gene
therapy applications: direct, indirect, and hybrid. The direct
method involves the injection of viral vectors directly into the
articular joint space to transduce local cells. Although long-
term persistence of transgene expression has been observed
with direct injection of AAV2,14 most of the transduction
occurs in soft tissues and it is difficult to localize the trans-
duction to specific cell types. Further, rapid dispersion of
viral particles from the joint space would prevent effective
transduction of repair cells that are recruited to the defect site
over time. Thus, the in vivo transduction efficiency remains
low and nonspecific transduction of adjacent tissues and
their transgene expression at undesired sites is usually ob-
served.15 The indirect approach involves the use of geneti-
cally modified cells,12 and/or biodegradable scaffolds that
release genetically modified cells.17,18 This leads to the site-
specific release of bioactive molecules important in tissue
regeneration, though temporary. In addition, this approach
requires ex vivo manipulation of cultured cells, which faces
high barriers with respect to clinical translation. The third
hybrid approach involves implantation of biodegradable
scaffolds embedded with genetic materials,19,20 leading to
direct and localized in situ delivery of bioactive vectors to the
host cells in proximity to the scaffold, as well as the sustained
expression of the transgene. Further, scaffolds can act as
support for injury-activated repair or progenitor cells, such
as BM-derived mesenchymal stem cells (BM-MSCs), to mi-
grate, attach, and differentiate at the defect site. Thus, the
hybrid method offers the advantages of site-specific locali-
zation, direct transduction of host repair cells, and sustained
transgene expression, while limiting the disadvantages of
indiscriminate transduction and requirement of ex vivo ma-
nipulations.
Our group has previously shown that AAV2-transfroming
growth factor-b1 (AAV2-TGF-b1) transduced human MSCs
(hMSCs) implanted into a 1.5-mm-diameter osteochondral
defect significantly improved cartilage regeneration over 12
weeks in vivo.12 These results demonstrated that AAV2 is a
suitable vector for gene delivery to improve the cartilage
repair potential of the MSCs. However, although the ex vivo
gene transfer is effective, the regulatory barriers for using
genetically modified cultured human cells for therapeutic
purposes clinically are extremely high. In addition, extrac-
tion and expansion of MSCs prolong the time before treat-
ment can be applied and are very expensive. Therefore, we
have explored the use of biodegradable scaffolds for release
and delivery of bioactive substances to host MSCs within
cartilage wound.21–24
Fibrin glue (FG) is a natural substance available for human
use clinically as a commercial product or readily prepared
from plasma for autologous applications.15 These properties
mean that laboratory findings may be more readily trans-
lated into potential human clinical applications than similar
findings with synthetic polymers. Despite being widely used
in clinical surgical practice as an adhesive and sealant for
hemostasis,25 only in recent years has the ability of FG to act
as a delivery scaffold received attention.26 Besides being
commercially available for sterile applications, it is non-
immunogenic, biodegradable, and malleable so that it can be
molded into irregular tissue defects. All of these advantages
make FG an appealing scaffold for preclinical translational
cartilage tissue engineering applications. It has been shown
that diluted FG produces a more open fibrin network com-
pared with undiluted FG scaffolds,27 and that FG can act as
an efficient scaffold for gene delivery.28–30
In the current study, we investigated the effect of different
fibrinogen dilutions during the preparation of FG scaffold on
the delivery of AAV2 and their early effects on human BM-
MSC (hBM-MSC) chondrogenesis in vitro. The aim of this
study was to test the hypotheses that diluted FG scaffolds
will release more viral particles, result in higher transduction




Chemicals were purchased from Sigma-Aldrich (St. Louis,
MO) unless otherwise stated. Twenty-four-well plates and
24-well plate inserts were purchased from BD Biosciences
(San Jose, CA). Commercially available Tisseel human fi-
brin sealant (Baxter, Deerfield, IL) was used to construct FG
hydrogels. Fibrinogen (100% of the original material con-
centration, lyophilized human fibrinogen reconstituted in
aprotinin fibrinolysis inhibitor) was prepared by serial dilu-
tion with phosphate-buffered saline (PBS; Gibco, Carlsbad,
CA) into four different concentrations: 25%, 50%, 75%, and
100% fibrinogen. Different dilutions of fibrinogen were
subsequently mixed with an equal volume (1:1 volume ratio)
of thrombin solution provided in the Tisseel kit (human
thrombin 400–625 IU/mL and calcium chloride 36–44 mmol/
mL). The resultant FG constructs were named 25%, 50%,
75%, and 100% FG, according to the fibrinogen dilution be-
fore thrombin activation.
Characterization of different FG concentrations
Clotting time. 100mL of different fibrinogen dilutions was
mixed with 100mL Thrombin-CaCl2 in a 96-well plate to make
25%, 50%, 75%, and 100% FG scaffolds. Change in the tur-
bidity of the FG scaffold solution was immediately measured
by a VersaMax UV-Vis spectrophotometer (Molecular De-
vices, Sunnyvale, CA) at 550 nm wavelength.31 The clotting
time was defined as the time at which the maximum value
was reached in the absorbance curve. Three replicates of each
FG scaffold concentrations were examined in this study.
Scanning electron microscopy. Three FG scaffolds con-
structed from 200 mL of different fibrinogen dilutions and
200 mL Thrombin-CaCl2 were used for scanning electron
microscopy (SEM) analysis. After fixation in 2.5% gluter-
aldehyde for 1 h and rinsing in PBS, FG scaffolds were de-
hydrated in increasing alcohol concentrations (30%, 50%,
70%, 90%, and 100%) for 15 min each, followed by hexam-
ethyldisilazane for 1 h. Once hexamethyldisilazane was re-
moved, the scaffolds were air-dried for an hour. Each FG
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scaffold was coated with an ultra-thin gold layer containing
a gold sputter coater for 2 min at 25 mA and observed under
an SEM ( JSM-6335F; Jeol USA, Inc., Peabody, MA). Two
separate images of each scaffold were captured. Pore size
diameter and thickness of fibrin fibers were measured for
each image using image analysis software, Metamorph
7.6.2.0 (Molecular Devices).
FG dissolution. Wet weight measurement: Different fi-
brinogen dilutions were mixed with an equal volume of
thrombin-CaCl2 and injected into uncoated 24-well plate
inserts with 8mm pores at 200 mL FG/insert, and incubated at
37C for 15 min to form hydrogels. The weight of each insert
was measured before injection of the fibrinogen/thrombin
solutions. Once the FG scaffolds had solidified, 500 mL PBS
was added on top of each inserts, and the inserts were placed
in a 24-well plate containing 1 mL PBS/well. After incuba-
tion at 37C for 10 min, inserts were removed, PBS aspirated,
surface PBS adsorbed by a filter paper, and the initial
weight of the hydrogels (W0) was recorded. FG hydrogels
were re-weighed (Wt) every 2 days to estimate the wet
weight fraction, which was defined as (W0 - Wt)/W0. Five
replicates of each FG concentration were examined in this
study.
Protein dissolution: The conditioned PBS from each well,
in which the FG hydrogels were incubated, was also col-
lected at the time of hydrogel wet weight measurement. The
amount of the protein dissolved and released into the PBS
was measured by UV-Vis spectroscopy (NanoDrop, Wil-
mington, DE) at 278 nm, which measures the absorbance of
the phenyl group of fibrinopeptide proteins. Fresh PBS was
used as blank control.
AAV2-CMV-GFP in vitro transduction
AAV2-CMV-GFP-loaded FG preparation. Double-stran-
ded AAV2-GFP with a cytomegalovirus promoter (dsAAV2-
eGFP, hereunder referred to as AAV2-CMV-GFP) was
prepared as previously described.32 The AAV2 particles were
packaged and purified using the adenovirus-free, triple-
plasmid transfection method. The titer (vector genome per
milliliter [vg/mL]) was determined by viral DNA dot blot
method.33 The stock AAV2-CMV-GFP titer was 3 · 1012 vg/mL.
The AAV2-CMV-GFP vector stock was added to the var-
ious fibrinogen preparations (25%, 50%, 75%, and 100%) to
obtain a final concentration of 6.25 · 1010 vg/mL. After vor-
texing for 3 min, the AAV2-CMV-GFP-loaded fibrinogen
solutions were mixed with an equal volume of thrombin-
CaCl2 and injected into uncoated 24-well plate inserts with
8 mm pores, at 200 mL/well. After gelation at 37C for 15 min,
prewarmed 500 mL Dulbecco’s modified Eagle’s medium
(DMEM; Gibco)–1% penicillin-streptomycin (Pen-strep; Gib-
co) was added to each insert. Three replicates of each AAV2-
CMV-GFP-loaded FG concentrations were examined in this
study.
AAV2-CMV-GFP released from the AAV2-CMV-GFP
loaded FGs and their direct transduction of mammalian cells
were assessed over 21 days. HEK-293 cells (ATCC, CRL-
1573, Manassas, VA) were maintained in DMEM, 10% fetal
bovine serum (Atlanta Biologicals, Lawrenceville, GA), and
1% Pen-strep at 37C and 5% CO2. Each day, *2.4 · 106 cells
were seeded onto 24-well plates at a seeding density of
100,000 cells/well and incubated for 24 h, after which the
medium was changed to serum-free DMEM–1% Pen-strep.
Inserts containing AAV2-CMV-GFP-loaded FGs were placed
into the wells of the 24-well plate seeded with HEK-293 cells
and incubated for an additional 24 h at 37C. The medium
was placed below and in the inserts to allow migration of
AAV2-CMV-GFP from the FG hydrogels to the seeded cells.
Photomicrographs of GFP-expressing cells were taken daily
using an Olympus DP71 camera (Olympus America, Center
Valley, PA) and Nikon Eclipse TE2000-U microscope (Nikon
Instruments Inc., Melville, NY). All GFP images presented in
Figure 4C–F had the contrast increased by the same value in
Adobe Photoshop CS4 (Adobe Systems, Inc., San Jose, CA) to
improve the GFP signal for print.
AAV2-CMV-GFP release from FG
Each day, the conditioned serum free medium from each
well was collected and preserved at - 80C until analysis. The
amount of AAV2-CMV-GFP released into the conditioned
medium from AAV2-CMV-GFP-loaded scaffolds was quan-
tified by quantitative polymerase chain reaction (qPCR). All
PCRs contained 0.5mL of conditioned medium in a total vol-
ume of 10mL using a commercially available pre-prepared
2 · real-time TaqMan PCR master mix (Applied Biosystems,
Foster City, CA). GFP-specific custom TaqMan forward
(GTCCGCCCTGAGCAAAGA) and reverse (TCCAGCAG
GACCATGTGATC) primers as well as FAM-labeled probes
(CCCAACGAGAAGCG) were used. All qPCRs were per-
formed with an ABI PRISM 7700 Sequence Detection System
(Applied Biosystems) according to the following program:
12 min at 95C, followed by 40 cycles of 15 s at 95C and 1 min
at 60C. Three replicates of each experimental group were
examined in this study.
In vitro transduction of AAV2-CMV-GFP
released from FG
Transduction efficiency was quantified using flow cy-
tometry and expressed as percentage of GFP-positive cells.
Both AAV2-CMV-GFP-transduced and -nontransduced
control cells were trypsinized, washed, and resuspended in
400mL of PBS with 1% bovine serum albumin and 2%
paraformaldehyde (both from Fischer Scientific, Fair Lawn,
NJ). Ten thousand events were collected using a BD Bios-
ciences LSR II (BD Biosciences, Franklin Lakes, NJ). The
percentage of GFP-positive cells was determined by defining
GFP-negative cells and gating out debris with FlowJo 7.6.1
software (Tree Star, Inc., Ashland, OR). Three replicates of
each experimental group were examined in this study.
AAV2-CMV-TGF-b1 in vitro transduction
AAV2-CMV-TGF-b1-loaded FG preparation. Double-
stranded AAV2-TGF-b1 with a cytomegalovirus promoter
(dsAAV2-TGF-b1, hereunder referred to as AAV2-CMV-
TGF-b1) was prepared as previously described
32 and purified
as described in the section AAV2-CMV-GFP-loaded FG
preparation. The stock AAV2-CMV-TGF-b1 titer was
2.5 · 1012 vg/mL.
The AAV2-CMV-GFP and AAV2-CMV-TGF-b1 vector
stocks were separately added to 50% and 100% fibrinogen
preparations to obtain a final concentration of 1.25 · 1011 vg/
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mL. After vortexing for 3 min, the AAV2-loaded fibrinogen
solutions were mixed with an equal volume of thrombin-
CaCl2 and injected into uncoated six-well plate inserts with
8 mm pores, at 1 mL/well. After gelation at 37C for 15 min,
prewarmed 3 mL chondrogenic medium–High-Glucose
DMEM supplemented with 1% Pen-strep, 10–7 M dexa-
methasone, 50mg/mL L-ascorbic acid-2-phosphate, 40mg/
mL proline (MP Biomedicals, Solon, OH), and 1% ITS +
Premix (BD, Franklin Lakes, NJ) was added to each insert.
Three replicates of 50% and 100% AAV2-CMV-TGF-b1-loa-
ded FGs were examined in this study against the 50% and
100% AAV2-CMV-GFP-loaded FGs.
AAV2-CMV-TGF-b1 released from the AAV2-CMV-TGF-
b1-loaded FGs and their direct transductions of hBM-MSCs
were assessed. The hBM-MSCs were obtained, maintained,
and characterized as previously described.34,35 About
4.8 · 106 cells were seeded onto six-well plates at a seeding
density of 200,000 cells per well and incubated for 24 h, after
which the medium was changed to a chondrogenic medium.
Inserts containing AAV2-CMV-GFP-loaded FGs and AAV2-
CMV-TGF-b1-loaded FGs were placed into the wells of the 6-
well plate seeded with hBM-MSCs and incubated for 24 h.
The medium was placed below and in the inserts to allow
migration of AAV2s from the FG hydrogels to the seeded
cells. After the removal of the inserts, the cells were incu-
bated for an additional 48 h at 37C. The conditioned serum
free medium and hBM-MSCs from each well were collected
separately and preserved at - 80C until analysis.
In vitro transduction of AAV2-CMV-TGF-b1 released
from FG
The level of TGF-b1 expression from hBM-MSCs was as-
sessed by determining the level of TGF-b1 in cell culture
supernatant using a commercially available ELISA (R&D
Systems, Inc., Minneapolis, MN) according to the manufac-
turer’s description, and using a CCL-64 mink lung-epithelial
growth inhibition assay as previously described with slight
modification.36,37 Briefly, the CCL-64 cell line (ATCC, CRL-
1573) was grown in DMEM, 10% fetal bovine serum, and 1%
Pen-strep at 37C in 5% CO2. CCL-64 cells were plated at
5,000 cell/well in 96-well plates and cultured in 100 mL of
normal growth media for 3 h. The medium was then changed
to 100 mL of serum-free DMEM-1% Pen-strep supplemented
with 10% of conditioned media from hBM-MSC culture. The
plates were incubated at 37C in 5% CO2 for 24 h, and then
20 mL reconstituted XTT reagent from In Vitro Toxicology
Assay Kit (Sigma-Aldrich) was added to each well for 2 h
incubation. The absorbance at 450 nm was measured using
VersaMax UV-Vis spectrophotometer (Molecular Devices).
Cartilage-specific gene expression was measured from hBM-
MSCs by quantitative reverse transcription–polymerase chain
reaction (qRT-PCR). Total RNA from the collected hBM-MSC
samples was extracted using the RNeasy Mini Kit (Qiagen,
Valencia CA). The predesigned human aggrecan and 18S
TaqMan primers were purchased from Applied Biosystems.
Human sox-9 custom forward (TGACCTATCCAAGCGCATT
ACCCA) and reverse (ATCATCCTCCACGCTTGCTCTGAA)
primers as well as FAM-labeled probe (AGGCCAACCTT
GGCTAAATGGAGCA) were purchased from Integrated
DNA Technologies (IDT, Coralville, IA). All samples contained
1mL of extracted RNA in a total volume of 10mL using a
commercially available pre-prepared 2 · real-time TaqMan
PCR master mix (Applied Biosystems). All qRT-PCRs were
performed with an ABI PRISM 7700 Sequence Detection Sys-
tem (Applied Biosystems) according to the following program:
12 min at 95C, followed by 40 cycles of 15 s at 95C and 1 min
at 60C. Relative expression levels normalized to 18S were
calculated using the 2 -DCt method.
Statistical analysis
Data are expressed as mean – standard error of mean.
Statistical analysis was performed using independent sam-
ples t-test for comparison between two samples (Fig. 5), and
one-way independent analysis of variance or one-way re-
peated measures analysis of variance with post hoc Turkey
for multiple comparisons (Figs. 1–4) using Statistical Package
for Social Studies (SPSS) 17.0 for Windows (IBM, Chicago,
IL). The significance level was set as p < 0.05.
Results
Clotting time
After activation of the different fibrinogen dilutions with
thrombin-CaCl2, there was an immediate change in the tur-
bidity of the solution. The clotting time, or the time of
maximal turbidity, was dependent on the fibrinogen con-
centration ( p < 0.001). Absorbance of the fibrin gel at 550 nm
increased with time for all fibrinogen dilutions until it
reached a plateau. The clotting time as a function of fibrin-
ogen concentration is displayed in Figure 1. Clotting time of
the 100% FG was significantly higher ( p < 0.05) than the di-
luted (25%, 50%, and 75%) FG scaffolds. Although there was
no significant difference in clotting time between the dilute
FG scaffolds, there was an increasing trend in clotting time
with increasing FG concentrations.
SEM analysis of the FG hydrogel microstructures
SEM analysis of pore size diameter of the FG scaffolds
showed that all four scaffolds had pore size diameters
ranging 50–1200 nm. However, there was a denser, hetero-
FIG. 1. Clotting time showed an increasing trend with in-
creasing fibrin glue (FG) concentrations. Clotting time of 100%
FG was statistically higher than diluted FGs. Bars represent
mean – standard error of mean; n = 3. *p < 0.05 compared with
100% FG.
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geneous distribution of pores in the 100% FG (Fig. 2D)
compared with the diluted FG hydrogels, which displayed a
more homogenous and larger pore size diameters (Fig. 2A–
C). The pore size of the 100% FG was significantly smaller in
diameter ( p < 0.05) than those of the diluted FG scaffolds
(Fig. 2E). The fiber thickness of the scaffolds, also assessed by
SEM, increased with increasing FG concentrations (Fig. 2F).
The increases in fiber thickness were significant between
scaffolds with different fibrinogen concentrations ( p < 0.001).
In vitro dissolution of the FG hydrogels
Analysis of in vitro FG dissolution in PBS showed a bi-
phasic pattern (Fig. 3A). Wet weight fraction result showed
that the dissolution rate is significantly affected by different
concentrations of FG scaffolds ( p < 0.001): 25% and 50% fi-
brinogen concentrations displayed a significantly higher rate
of dissolution than 75% and 100% FG scaffolds. The first
spike in dissolution occurred at day 2 for the 25% and 50%
FG scaffolds, where the hydrogels lost *35% and 15% of
their initial weight, respectively. This was followed by a
second spike at day 8 when the hydrogels lost *80% of their
initial weight. For the 75% and 100% FG scaffolds, the two
spikes in dissolution occurred later at days 6 and 12, with
loss of 20% and 90% of the initial weight for the respective
time points. The pattern of protein release, observed by UV-
vis spectroscopy (Fig. 3B), correlates well with the wet
weight fraction finding, by being significantly affected by the
percentage of fibrinogen ( p < 0.001). As well, the biphasic
pattern of absorbance peaks that reflects most weight dis-
solution into the conditioned PBS can be noted.
Quantification of the amount of released
AAV2-CMV-GFP from FG hydrogels
The amount of AAV2-CMV-GFP released into the condi-
tioned media from the AAV2-CMV-GFP-loaded FG scaffolds
is significantly affected by different concentrations of FG
scaffolds ( p < 0.001), and also displays a biphasic pattern
(Fig. 4A). The spikes in the amount of AAV2-CMV-GFP re-
leased into the media occurred at day 2 and 9 for 25% and
50% FG scaffolds. In contrast, the spikes in the amount of
AAV2-CMV-GFP released into the media occurred at day 2
and 15 for 75% and 100% FG scaffolds. Approximation of the
area under the curves in Figure 4A suggests that the vector
genomes of AAV2-CMV-GFP released into the media from
75% and 100% FG scaffolds were lower than that of 25% and
50% FG scaffolds.
Quantification of mammalian cell transduction
efficiency of released AAV2-CMV-GFP
The percentage of GFP-positive cells from transduction of
AAV2-CMV-GFP released into the conditioned media from
the AAV2-CMV-GFP-loaded FG scaffolds is also significantly
affected by different concentrations of FG scaffolds ( p < 0.001),
and showed a biphasic pattern (Fig. 4B). This pattern is similar
to those of the FG dissolution (Fig. 3) and AAV2-CMV-GFP
release (Fig. 4A). FG scaffolds with 25% and 50% fibrinogen
concentrations yielded significantly higher percentage of GFP-
positive cells than the 75% and 100% FG scaffolds. There were
spikes in the percentage of GFP-positive cells at days 1 and 8
for all FG scaffolds, which correlate with the biphasic release
FIG. 2. Scanning electron microscopy analyses of FG hydrogels. (A–D) SEM photographs of freeze-dried 25%, 50%, 75%,
and 100% FGs, respectively. (E) Pore size analysis of the FG cross sections showed that the pore diameter of the 100% FG was
significantly lower than those of the diluted FGs. (F) FG fiber thickness analysis showed an increasing trend with increasing
concentration of FG. The fiber thickness of each group was statistically different from each other. Bars represent
mean – standard error of mean; n = 3. *p < 0.05, #p < 0.001.
RELEASE OF BIOACTIVE AAV FROM FIBRIN SCAFFOLDS 1973
FIG. 3. In vitro FG dissolution. (A) Wet weight fraction analysis and (B) absorbance at 278 nm, reflecting the amount of
phenyl group of fibrinopeptide proteins dissolved in the conditioned phosphate-buffered saline, showed a biphasic disso-
lution pattern for all FGs. Data markers represent mean – standard error of mean; n = 5. *p < 0.05 between 25 and 50% FGs and
75% and 100% FGs.
FIG. 4. In vitro characterization of adeno-associated viruses serotype 2 (AAV2)-CMV-GFP-loaded FG scaffolds. (A) Vector
genomes (vg) of AAV2-CMV-GFP released into 1 mL of conditioned media and (B) percentage of GFP-positive HEK-293 cells
show biphasic AAV2-CMV-GFP release and corresponding spikes in percentage of GFP-positive cells. Data markers rep-
resent mean – standard error of mean; n = 3. *p < 0.05 between 25% and 50% FGs and 75% and 100% FGs. (C–F) Fluorescent
and bright-field photomicrographs of HEK-293 cells incubated with AAV2-CMV-GFP-loaded 25%, 50%, 75%, and 100% FGs
at day 8 correlates with the quantitative findings in A and B.
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pattern of high amounts of AAV2-CMV-GFP at these time
points (Fig. 4A). Although 75% and 100% FG scaffolds
showed similar biphasic spikes in the percentage of GFP-
positive cells, the response was significantly lower compared
with 25% and 50% FG scaffolds. Photomicrographs of GFP-
expressing cells taken daily confirmed quantitative findings
by flow cytometry (Fig. 4C–F).
Quantification and functional analysis of TGF-b1
expression from hBM-MSCs transduced with released
AAV2-CMV-TGF-b1
The amount of TGF-b1 synthesized by hBM-MSCs and
released into the conditioned medium is significantly af-
fected by different concentrations of FG scaffolds (Fig. 5A, B).
Cells incubated with 50% FG loaded with AAV2-CMV-TGF-
b1 made 2.5-fold more active-TGF-b1 than those incubated
with 100% FG loaded with AAV2-CMV-TGF-b1, ( p = 0.017,
Fig. 5A). As well, the conditioned medium from the hBM-
MSC culture that was incubated with the 50% FG loaded
with AAV2-CMV-TGF-b1 resulted in greater inhibition of
CCL-64 cell proliferation (Fig. 5B), measured via mitochon-
drial activity ( p = 0.002). The different concentrations of
AAV2-CMV-TGF-b1-loaded FG scaffolds also affected the
cartilage-specific gene expression of the hBM-MSCs (Fig. 5C).
Human sox-9 and aggrecan mRNA expressions were signifi-
cantly higher for 50% FG versus 100% FG ( p = 0.049 and
p = 0.009, respectively). All the results were normalized
against values from AAV2-CMV-GFP-loaded FG scaffolds of
the same percentage fibrinogen concentration to account for
the effects of viral transduction, FG, and endogenous TGF-b1
production by hBM-MSCs.
Discussion
Tissue engineering scaffolds allow for the delivery of cells
or diffusible factors that can act locally to promote tissue
regeneration.38,39 The combination of gene therapy and tis-
sue engineering offers the potential to direct progenitor cells’
proliferation and differentiation into functional tissue re-
placement.15 We have previously shown that hMSCs trans-
duced with AAV-TGF-b1 improved the in vivo cartilage
repair when the ex vivo transduced cells were implanted into
osteochondral defects of athymic rats.12 However, in an ef-
fort to move beyond ex vivo gene transfer, the current focus
of the project is on in situ delivery of therapeutic transgenes,
such as TGF-b1, directly to host MSCs residing in cartilage
wounds using biodegradable scaffolds. This strategy can be
thought of as ‘‘augmenting’’ microfracture, which is an ac-
cepted human clinical standard for treatment of full-thickness
cartilage defects.40 The goal of this strategy is to induce lo-
calized exogenous transgene expression in repair/progenitor
cells infiltrating into the scaffold for sustained release of these
factors at the site of injury. Strategies that combine scaffolds,
drug delivery technology, and gene therapy have the po-
tential to provide more effective tissue regeneration with
significant improvements on safety and cost issues compared
to currently available therapies.
Although numerous novel synthetic and natural polymers
have been investigated for cartilage tissue engineering
studies,21,23,24 usage of an FDA-approved and autologous
biomaterial as an AAV2-releasing scaffold can accelerate the
transition of basic science research into human clinical
studies. FG is a biomaterial widely used in clinical practice
and tissue engineering applications. As well, dilute FG has
FIG. 5. In vitro characteriza-
tion of AAV2-CMV-TGF-b1-
loaded FG scaffolds: (A) Mean
fold amount of active trans-
forming growth factor-beta1
(TGF-b1) released into the
conditioned media showed
increased production of
TGF-b1 from human bone
marrow-derived mesenchy-
mal stem cells (hBM-MSCs)
incubated with 50% FG. (B)
Mean fold XTT absorbance
measurement from CCL-64
cells showed higher TGF-b1-
mediated growth inhibition in
samples incubated with con-
ditioned media from 50% FG.
(C) Mean fold human sox-9






genes in cells incubated with
50% FG. Data were normal-
ized against values from AAV2-CMV-GFP-loaded FG scaffolds of the same percentage fibrinogen concentration to account
for the effects of viral transduction, FG, and endogenous TGF-b1 production by hBM-MSCs. Bars represent mean – standard
error of mean; n = 3. *p < 0.05 between 50% and 100% FGs.
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been successfully used to treat cartilage wounds in a pilot
human clinical study.22 However, studies on its use as a
delivery scaffold for gene vectors are limited, and only ad-
enovirus delivery has been investigated for the delivery of
viral vectors.26 FG has been investigated as a delivery scaf-
fold for controlled release of adenovirus in a rabbit ear ulcer
model29 and for perivenous adventitial gene transfer,30 and
was shown to provide enhanced in vivo transgene expression
over adenovirus transduction without FG scaffold. For car-
tilage tissue engineering purposes, FG scaffolds with non-
viral copolymer-protected polyethylenimine-DNA vectors
achieved sustained release of the gene over 20-day period
and successful in vitro transfection of human keratinocytes
and rabbit articular chondrocytes.28
Nonetheless, FG formulation for AAV2 delivery has not
been optimized. The fibrinogen/thrombin concentration in
the FG preparation has been shown to affect the structural
properties of the scaffold, and in turn influence the prolif-
eration rate and morphology of hMSCs.27 Therefore, alter-
ations in FG scaffold microstructure can influence its
function as a delivery scaffold for AAV2. The aim of the
current study was to assess, in vitro, the structural charac-
teristics of FG hydrogels containing varying fibrinogen con-
centrations, their AAV2-particles release kinetics, and
subsequent transgene expression in target cells for articular
cartilage tissue engineering.
Undiluted 100% FG scaffold had longer gelation time
compared with diluted scaffolds, which may be explained by
data from SEM analysis, which showed that 100% FG scaf-
folds formed a denser scaffold with smaller pore sizes and
thicker fibrin fibers than diluted FG scaffolds. In contrast,
diluted FG scaffolds had a more open fibrin network, which
was reflected by their shorter clotting times. Consistent with
another finding,27 diluted FGs had a more homogenous
structure than undiluted 100% scaffold.
FG scaffolds dissolved over time in PBS, which was shown
by the decrease in the wet weight over time and by the
change in absorbance measurements of the phenyl group of
the fibrinopeptide over time. Dissolution of the FG scaffolds
coincided with the amount of AAV2-CMV-GFP released into
the conditioned media. In addition, both the dissolution of
the scaffold and the amount of AAV2-CMV-GFP released
into the media occurred in a biphasic burst fashion, consis-
tent with a typical hydrogel bulk-degradation pattern. The
burst release pattern of AAV2-CMV-GFP was similar to the
percentage of GFP-positive HEK-293 cells. There were more
GFP-positive cells when a greater amount of AAV2-CMV-
GFP was released into the media. Both the amount of AAV2-
CMV-GFP released and the number of GFP-positive cells is
higher in wells with 25% and 50% FG scaffolds than in those
with 75% and 100% FG scaffolds. In addition to dissolution
pattern of the FG scaffold, the more open fibrin network of
the 25% and 50% FG scaffolds may contribute to greater
release of AAV2-CMV-GFP and the higher percentage of
GFP-positive cells compared with 75% and 50% FG scaffolds.
These in vitro studies showed that commercial strength 100%
as well as 75% FGs are less efficient at releasing AAV2 par-
ticles, and that dilute 25% and 50% FGs are more effective.
Viral particles released from dilute FGs retained the ability to
transduce HEK-293 cells up to 17 days in vitro.
In contrast to our findings with AAV2, a previous study
investigating different concentrations of FG scaffold loaded
with adenovirus had achieved optimal viral releasing prop-
erties with the higher fibrinogen concentration.41 However,
this was observed with adenovirus vector and with a diluted
thrombin concentration. Compared with adenovirus, AAV is
much smaller and has the advantages of improved safety
profile and longer transgene persistence.14 In addition, lower
thrombin concentration decreases the rate of fibrin cross-
linking.26 Since in vivo FG decomposition will be accelerated
via plasmin-mediated fibrin degradation in addition to dif-
fusion-mediated dissolution, FGs prepared with undiluted
thrombin are more likely to persist and release AAV2 particles
longer for animal or human applications.
Although many more dilutions of FG at smaller incre-
ments could be studied to further assess the AAV2 release
kinetics, especially with lower concentrations of FG, the four
dilutions were chosen to support the goal of evaluating FG
concentrations potentially useful for in vivo clinical applica-
tions. As well, FG dilutions of 25% approach the lower limit
to achieve a clinically functional scaffold structure.41 For this
reason, 50% and 100% FGs were chosen for subsequent
studies with AAV2-CMV-TGF-b1.
As our ultimate goal is to develop a localized AAV2 de-
livery system for cartilage tissue engineering, we further
explored the concentrations of 50% and 100% FGs for de-
livery of AAV2 encoding for a therapeutic gene useful for
cartilage regeneration. Transforming growth factor-b1 (TGF-
b1) has long been shown to consistently induce BM-MSC
chondrogenesis in vitro.34,42 We also have previously shown
that implantation of AAV2-CMV-TGF-b1-transduced hMSCs
into osteochondral defects has improved cartilage repair
in vivo.12 Therefore, we compared AAV2-CMV-TGF-b1 de-
livery from the 50% and 100% FGs to hBM-MSCs in vitro.
The studies on FG scaffold delivery of therapeutic-AAVs,
versus reporter gene-AAVs, especially for their chondrogenic
effects, have been limited to date.26 hBM-MSCs cultured with
50% FG-AAV2-CMV-TGF-b1 construct had higher concen-
tration of active TGF-b1, which resulted in greater inhibition
of CCL-64 cell proliferation, and higher cartilage-specific
gene expression levels in transduced hBM-MSCs.
In summary, we have demonstrated that varying the fi-
brinogen concentrations in FG constructs changes the struc-
tural and functional characteristics of the scaffold for gene
delivery. Diluting the fibrinogen concentration yields a scaf-
fold with a network of larger pores and thinner fibers, which
reduces entrapment and subsequently enhances the release of
AAV2 particles. Lower concentration FG scaffolds have also
been shown to promote greater proliferation for hMSCs,
which are the principal cell types recruited for in situ chon-
drogenesis.27 Therefore, implantation of diluted FG scaffolds
containing bioactive AAV2 vectors have the potential to im-
prove articular cartilage regeneration and be translated for
clinical cartilage tissue engineering. Further in vivo studies are
planned using small and large animal models to validate the
enhanced repair potential of diluted FG scaffolds with thera-
peutic AAV2-TGF-b1 for localized in situ cartilage tissue en-
gineering before translation into the clinical setting.
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